Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Current Deferred Revenue (2021 - 2025)

Roivant Sciences' Current Deferred Revenue history spans 5 years, with the latest figure at $1.2 million for Q1 2025.

  • For Q1 2025, Current Deferred Revenue fell 71.98% year-over-year to $1.2 million; the TTM value through Mar 2025 reached $1.2 million, down 71.98%, while the annual FY2025 figure was $1.2 million, 71.98% down from the prior year.
  • Current Deferred Revenue reached $1.2 million in Q1 2025 per ROIV's latest filing, down from $3.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $12.4 million in Q1 2023 to a low of $1.2 million in Q1 2025.
  • Average Current Deferred Revenue over 5 years is $6.4 million, with a median of $5.9 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: soared 71.46% in 2022, then tumbled 74.83% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $5.9 million in 2021, then soared by 31.73% to $7.8 million in 2022, then plummeted by 39.78% to $4.7 million in 2023, then plummeted by 35.31% to $3.0 million in 2024, then crashed by 61.54% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Current Deferred Revenue are $1.2 million (Q1 2025), $3.0 million (Q4 2024), and $3.4 million (Q3 2024).